MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

PHASE4CompletedINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

November 21, 2017

Primary Completion Date

November 19, 2021

Study Completion Date

November 19, 2021

Conditions
SchizophreniaAntipsychoticsLong-Acting InjectionLAIAripiprazole
Interventions
DRUG

Abilify maintena

Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)

Trial Locations (27)

17089

Yong-In Mental Hospital, Yongin-si

22332

Inha University Hospital, Incheon

27376

Konkuk University Chungju Hospital, Chungju

32601

Gongju National Hospital, Gongju

35233

Eulji University Hospital, Daejeon

35365

Konyang University Hospital, Daejeon

63241

Jeju National University Hospital, Jeju City

Unknown

Hanyang University Guri Hospital, Guri-si

Cha Bundang Medical Center, Seongnam-si

Seoul National University Bundang Hospital, Seongnam-si

The Catholic University of Korea Uijeongbu ST. Mary'S Hospital, Uijeongbu-si

Chonbuk National University Hospital, Jeonju

Keimyung University Dongsan Medical Center, Daegu

Kyungpook National University Hospital, Daegu

Yeungnam University Medical Center, Daegu

Chungnam National University Hospital, Daejeon

Chonnam National University Hospital, Gwangju

International St. Mary's Hospital, Incheon

Inje University Haeundae Paik Hospital, Pusan

Pusan National University Yangsan Hospital, Pusan

Eulji General Hospital, Seoul

Ewha Womans University Mokdong Hospital, Seoul

Korea University Anam Hospital, Seoul

Kyung Hee University Hospital, Seoul

Seoul National University Hosipital, Seoul

03181

Kangbuk Samsung Hospital, Seoul

06351

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY